On June 5, 2025, Aclaris Therapeutics, Inc. shareholders approved the 2025 Equity Incentive Plan and increased authorized common stock from 200 million to 400 million shares. Approximately 76.5% of shares were represented at the meeting with key proposals passing significantly.